摘要
多年来,Polo样激酶1(Plk1)作为治疗靶点已经获得巨大的效益。Plk1是高度保守的丝氨酸/苏氨酸激酶之一,在真核细胞有丝分裂,细胞分裂和DNA损伤反应起着关键作用。本文总结了Plk1在细胞周期的功能、其在治疗儿童癌症方面的作用和作为预后因素的价值。此外,本文介绍了药物抑制的研究进展以及以Plk1为靶点的小分子药物治疗癌症的化疗方法的发展。最后,对PLK1抑制剂的临床试验进行了简要回顾。
关键词: 化疗,抑制剂,小儿肿瘤,PLK1,化疗,抑制剂,小儿肿瘤,PLK1,放疗,治疗。
Current Drug Targets
Title:PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Volume: 17 Issue: 14
Author(s): Julia Alejandra Pezuk, Elvis Terci Valera, María Sol Brassesco
Affiliation:
关键词: 化疗,抑制剂,小儿肿瘤,PLK1,化疗,抑制剂,小儿肿瘤,PLK1,放疗,治疗。
摘要: Over the years, polo-like kinase 1 (PLK1) has garnered great interest as a therapeutic target. The PLK1 is a member of a highly conserved serine/threonine kinase family that plays pivotal roles in mitosis, cytokinesis and DNA damage response in eukaryotic cells. In this review, we summarize the functions of PLK1 during cell cycle progression, its roles in human pediatric cancer and its value as a prognostic factor. Furthermore, we introduce the advances in pharmacological inhibition and the newly chemotherapeutic development of small-molecules to target PLK1 in cancer treatment. Finally, clinical trials with PLK1 inhibitors are briefly reviewed.
Export Options
About this article
Cite this article as:
Julia Alejandra Pezuk, Elvis Terci Valera, María Sol Brassesco , PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors, Current Drug Targets 2016; 17 (14) . https://dx.doi.org/10.2174/1389450116666150825120235
DOI https://dx.doi.org/10.2174/1389450116666150825120235 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry Integration of Pharmacogenomics and Pharmacometrics to Support Drug Development, Regulatory and Therapeutic Decisions
Current Pharmacogenomics and Personalized Medicine Green Tea Extract-Patents and Diversity of Uses
Recent Patents on Food, Nutrition & Agriculture Oxidative Stress in Patients with COPD
Current Drug Targets Current Advances and Applications of Diagnostic Microfluidic Chip: A Review
Current Drug Therapy SRC-3/AIB-1 may Enhance Hepatic NFATC1 Transcription and Mediate Inflammation in a Tissue-Specific Manner in Morbid Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist
Current Rheumatology Reviews A Comprehensive Review on Liver Targeting: Emphasis on Nanotechnology- based Molecular Targets and Receptors Mediated Approaches
Current Drug Targets Image Guided Biopsy of Musculoskeletal Lesions with Low Diagnostic Yield
Current Medical Imaging Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics Modern Treatments for Gliomas Improve Outcome
Current Cancer Therapy Reviews Gut Alterations in Septic Patients: A Biochemical Literature Review
Reviews on Recent Clinical Trials Novel Vitreous Modulators for Pharmacologic Vitreolysis in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects
Current Bioinformatics Transglutaminase-Catalyzed Crosslinking in Neurological Disease: From Experimental Evidence to Therapeutic Inhibition
CNS & Neurological Disorders - Drug Targets Redox State, Oxidative Stress, and Molecular Mechanisms of Protective and Toxic Effects of Bilirubin on Cells
Current Pharmaceutical Design Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Tetralogy of Fallot and Hypoplastic Left Heart Syndrome – Complex Clinical Phenotypes Meet Complex Genetic Networks
Current Genomics Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism